Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY vs FIORINAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Relief of tension-type headache,Relief of migraine headache (off-label)
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Butalbital 35-50 hours, aspirin 15-20 minutes (salicylate 2-3 hours at low doses, >20 hours at high doses), caffeine 3-5 hours. Prolonged in hepatic/renal impairment.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Butalbital is extensively metabolized in the liver via hydroxylation and glucuronidation, primarily by CYP2C9 and CYP2C19. Aspirin is hydrolyzed to salicylic acid, then conjugated with glycine (salicyluric acid) and glucuronidated. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Renal: 60% butalbital (mostly unchanged), 10% aspirin (salicylates, majorly as metabolites), 3% caffeine (metabolites and unchanged). Fecal: <5% overall.
>99% bound to albumin and alpha-1-acid glycoprotein.
Butalbital 20-40% (albumin), aspirin 80-90% (albumin, concentration-dependent), caffeine 25-36% (albumin).
4.9 L/kg (high distribution into tissues).
Butalbital 0.8 L/kg, aspirin 0.15-0.2 L/kg, caffeine 0.6-0.8 L/kg. Indicates extensive tissue distribution for butalbital and caffeine.
Oral: 87% (tablet and solution); IM: 100%.
Oral: butalbital ~100%, aspirin 50-75% (first-pass metabolism), caffeine ~100%.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen accumulation. Use with caution in moderate impairment.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For mild to moderate (Child-Pugh A or B), reduce dose by 50% or extend dosing interval.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Not recommended for pediatric use; safety and efficacy not established.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
Start at lowest effective dose (e.g., 1 capsule every 4 hours) due to increased sensitivity to butalbital (sedation, confusion) and risk of acetaminophen hepatotoxicity; maximum daily acetaminophen dose 2 g.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
None.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Risk of Reye's syndrome in children with viral illness,Aspirin hypersensitivity (e.g., asthma, nasal polyps),Gastrointestinal bleeding and ulceration,Hepatic impairment due to butalbital metabolism,Caffeine overdose from excessive use,Dependence and withdrawal with prolonged butalbital use
Known hypersensitivity to aripiprazole or any of its excipients.
Hypersensitivity to butalbital, aspirin, or caffeine,Active peptic ulcer disease,Hemophilia or bleeding disorders,Concomitant use of anticoagulants,Children with chickenpox or influenza-like symptoms (risk of Reye's syndrome),Severe hepatic or renal impairment,Porphyria
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Avoid excessive caffeine intake from coffee, tea, energy drinks, or chocolate as it may compound caffeine's stimulant effects and increase anxiety or insomnia. Alcohol should be strictly avoided due to additive CNS depression and increased GI bleeding risk with aspirin. No specific food restrictions besides moderation of caffeine-containing foods.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause premature closure of ductus arteriosus. Third trimester: Aspirin increases risk of intracranial hemorrhage, premature closure of ductus arteriosus; butalbital may cause neonatal withdrawal. Caffeine is not a major teratogen but high doses may increase miscarriage risk.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Aspirin excreted in milk (M/P ratio ~0.03-0.3); risk of Reye syndrome. Butalbital excreted in low amounts; may cause neonatal sedation. Caffeine excreted (M/P ~0.5-0.7); may cause irritability. Avoid breastfeeding during chronic use.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Due to increased renal clearance and volume of distribution, butalbital may require dose increase; aspirin may need higher doses due to increased plasma volume; no specific adjustment for caffeine. Monitor clinical response and toxicity.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
FIORINAL (butalbital/aspirin/caffeine) is a barbiturate-containing combination analgesic. Due to butalbital's high abuse potential and risk of withdrawal, it is reserved for tension-type headaches refractory to non-barbiturate therapies. Monitor for signs of barbiturate dependence, and limit quantity dispensed. Avoid in patients with porphyria, severe hepatic impairment, or hemorrhagic disorders (aspirin component). Caffeine may exacerbate anxiety or insomnia.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
This medication contains butalbital, which can be habit-forming; do not exceed prescribed dose or duration.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Do not drive or operate heavy machinery until you know how this drug affects you.,Take with food to reduce stomach upset; if you experience black or bloody stools, stop and seek immediate medical attention (signs of GI bleeding from aspirin).,Do not use more than directed; sudden discontinuation can cause withdrawal symptoms (anxiety, tremors, seizures).,Keep out of reach of children; overdose may be fatal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY vs FIORINAL, answered by our medical review team.
ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. FIORINAL is a Barbiturate Analgesic Combination that works by FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY and FIORINAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. The standard adult dose of FIORINAL is: 1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY and FIORINAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. FIORINAL is classified as Category C. First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause prem. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.